Abstract
Activated glial cells are capable of generating various inflammatory mediators, including cytokines, nitric oxide and reactive oxygen species. These potentially neurotoxic molecules have been suggested to play a role in the etiology and development of depression. Accumulating evidence indicates that antidepressants have inhibitory effects on inflammatory activation of glial cells and confer neuroprotection under neuropathological conditions. Such efficacy of antidepressants appears to depend on suppressing microglial production of inflammatory substances and up-regulating both astrocytic secretion of neurotrophins and astrocytic glutamine synthase, which converts neurotoxic glutamate into non-toxic glutamine. Therefore, glial cells, both as source and target of inflammatory molecules, may represent a potential promising target involved in the pathophysiology of depression. Moreover, antidepressants have the possibility to be useful treatment, not only for depression, but for a broad spectrum of neuroinflammatory and neurodegenerative disorders where the pathogenesis is associated with glial activation.
Keywords: Antidepressants, anti-inflammatory effect, astrocyte; cytokine, depression, microglia, nitric oxide, reactive oxygen species.
Current Drug Targets
Title:Glia: An Important Target for Anti-Inflammatory and Antidepressant Activity
Volume: 14 Issue: 11
Author(s): Sadayuki Hashioka, Tsuyoshi Miyaoka, Rei Wake, Motohide Furuya and Jun Horiguchi
Affiliation:
Keywords: Antidepressants, anti-inflammatory effect, astrocyte; cytokine, depression, microglia, nitric oxide, reactive oxygen species.
Abstract: Activated glial cells are capable of generating various inflammatory mediators, including cytokines, nitric oxide and reactive oxygen species. These potentially neurotoxic molecules have been suggested to play a role in the etiology and development of depression. Accumulating evidence indicates that antidepressants have inhibitory effects on inflammatory activation of glial cells and confer neuroprotection under neuropathological conditions. Such efficacy of antidepressants appears to depend on suppressing microglial production of inflammatory substances and up-regulating both astrocytic secretion of neurotrophins and astrocytic glutamine synthase, which converts neurotoxic glutamate into non-toxic glutamine. Therefore, glial cells, both as source and target of inflammatory molecules, may represent a potential promising target involved in the pathophysiology of depression. Moreover, antidepressants have the possibility to be useful treatment, not only for depression, but for a broad spectrum of neuroinflammatory and neurodegenerative disorders where the pathogenesis is associated with glial activation.
Export Options
About this article
Cite this article as:
Hashioka Sadayuki, Miyaoka Tsuyoshi, Wake Rei, Furuya Motohide and Horiguchi Jun, Glia: An Important Target for Anti-Inflammatory and Antidepressant Activity, Current Drug Targets 2013; 14 (11) . https://dx.doi.org/10.2174/13894501113146660214
DOI https://dx.doi.org/10.2174/13894501113146660214 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neurogenic plasticity of mesenchymal stem cell, an alluring cellular replacement for traumatic brain injury
Current Stem Cell Research & Therapy Selenium and Clinical Trials: New Therapeutic Evidence for Multiple Diseases
Current Medicinal Chemistry Yin and Yang of Polyphenols in Cancer Prevention: A Short Review
Anti-Cancer Agents in Medicinal Chemistry Flavones from Root of Scutellaria Baicalensis Georgi: Drugs of the Future in Neurodegeneration?
CNS & Neurological Disorders - Drug Targets Neuron-Microglia Interaction in Neuroinflammation
Current Protein & Peptide Science Recent Advances of Fluorescent Technologies for Drug Discovery and Development
Current Pharmaceutical Design Subject Index To Volume 6
Current Molecular Medicine Neurotensin NTS1-Dopamine D2 Receptor-Receptor Interactions in Putative Receptor Heteromers: Relevance for Parkinson`s Disease and Schizophrenia
Current Protein & Peptide Science Molecular Mechanisms Determining Opposed Functional States of Microglia
Current Neuropharmacology Cell Life Versus Cell Longevity: The Mysteries Surrounding the NAD+ Precursor Nicotinamide
Current Medicinal Chemistry Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer’s Disease and Less Well-Known Diseases
Current Medicinal Chemistry Noradrenergic System in Down Syndrome and Alzheimer’s Disease A Target for Therapy
Current Alzheimer Research Effects of Therapeutic Hypothermia on the Glial Proteome and Phenotype
Current Protein & Peptide Science How Would Composite Traditional Chinese Medicine Protect the Brain – An Example of the Composite Formula “Pien Tze Huang”
Current Medicinal Chemistry Dangerous Liaisons: Tau Interaction with Muscarinic Receptors
Current Alzheimer Research Patent Selections :
Recent Patents on CNS Drug Discovery (Discontinued) To Die or Not to Die: That is the Autophagic Question
Current Molecular Medicine CXCL8 as a Potential Therapeutic Target for HIV-Associated Neurocognitive Disorders
Current Drug Targets Editorial [Hot topic: New Therapeutic Strategies for Treatment of Neurodegenerative Diseases (Executive Editor: Aleksey G. Kazantsev)]
Current Pharmaceutical Design Neurogenesis and Alzheimers Disease: Biology and Pathophysiology in Mice and Men
Current Alzheimer Research